Novo Nordisk says Ozempic helped patients with Type 2 diabetes in one new way
Novo Nordisk A.S. said Tuesday a five-year trial of its Ozempic weight-loss drug helped reduce the risk of kidney disease-related...
Novo Nordisk A.S. said Tuesday a five-year trial of its Ozempic weight-loss drug helped reduce the risk of kidney disease-related...
Viking Therapeutics Inc.’s stock rose another 8% Wednesday to extend its week-to-date gains to 145%, as analysts weighed in on...
Viking Therapeutics Inc.’s stock soared 100% early Tuesday, after the company announced positive results from a Phase 2 trial of...
Small-cap stocks can help investors diversify from the S&P 500, which is heavily weighted to the largest U.S. tech players....
From our recent travels around India, it appears that the world’s most populous country could be poised for long-term growth....
The obesity drugs that powered huge investor gains in 2023 are poised to inspire more corporate dealmaking, scientific breakthroughs and...
French pharmaceuticals giant Sanofi SAN, -0.44% on Thursday said it would be halting development of a promising cancer treatment after...
During the bull market of 2023, the “Magnificent Seven” stocks have dominated financial media coverage, and rightly so. There is...
Roche has agreed to buy obesity-drug developer Carmot Therapeutics for up to $3.1 billion, as the world’s top drugmakers rush...